MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3390/jcm10040734

Медицинская библиотека · Journal of clinical medicine · 2021

Percutaneous Mitral Valve Repair: Outcome Improvement with Operator Experience and a Second-Generation Device.

Freixa Xavier, Estévez-Loureiro Rodrigo, Carrasco-Chinchilla Fernando, Millán Xavier, Amat-Santos Ignacio, Regueiro Ander, Nombela-Franco Luis, Pascual Isaac, Cid Belen, López-Mínguez José Ramón, Hernández-Antolín Rosa Ana, Cruz-González Ignacio, Andraka Leire, Goicolea Javier, Ruíz-Quevedo Valeriano, Díez Jose Luís, Berenguer Alberto, Baz José Antonio, Pan Manuel, Benito-González Tomas, Briales Juan H Alonso, Li Chi Hion, Sanchis Laura, Serrador Ana, Jiménez-Quevedo Pilar, Avanzas Pablo, Salido Luisa, Fernández-Vázquez Felipe, Hernández-García José Maria, Arzamendi Dabit

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND AND AIM: Recent randomized data comparing percutaneous mitral valve repair (PMVR) versus optimal medical treatment in patients with functional MR (FMR) seemed to highlight the importance of the learning curve not only for procedural outcomes but also for patient selection. The aim of the study was to compare a contemporary series of patients undergoing PMVR using a second-generation Mitraclip device (Mitraclip NT) with previous cohorts treated with a first-generation system.

METHODS

This multicenter study collected individual data from 18 centers between 2012 and 2017. The cohort was divided into three groups according to the use of the first-generation Mitraclip during the first (control-1) or second half (control-2) or the Mitraclip NT system.

RESULTS

A total of 545 consecutive patients were included in the study. Among all, 182 (33.3%), 183 (33.3%), and 180 (33.3%) patients underwent mitral repair in the control-1, control-2, and NT cohorts, respectively. Procedural success was achieved in 93.3% of patients without differences between groups. Major adverse events did not statistically differ among groups, but there was a higher rate of pericardial effusion in the control-1 group (4.3%, 0.6%, and 2.6%, respectively; p = 0.025). The composite endpoint of death, surgery, and admission for congestive heart failure (CHF) at 12 months was lower in the NT group (23.5% in control-1, 22.5% in control-2, and 8.3% in the NT group; p = 0.032).

CONCLUSIONS

The present paper shows that contemporary clinical outcomes of patients undergoing PMVR with the Mitraclip system have improved over time.

Для цитирования: Freixa Xavier, Estévez-Loureiro Rodrigo, Carrasco-Chinchilla Fernando, Millán Xavier, Amat-Santos Ignacio, Regueiro Ander, Nombela-Franco Luis, Pascual Isaac, Cid Belen, López-Mínguez José Ramón, Hernández-Antolín Rosa Ana, Cruz-González Ignacio, Andraka Leire, Goicolea Javier, Ruíz-Quevedo Valeriano, Díez Jose Luís, Berenguer Alberto, Baz José Antonio, Pan Manuel, Benito-González Tomas, Briales Juan H Alonso, Li Chi Hion, Sanchis Laura, Serrador Ana, Jiménez-Quevedo Pilar, Avanzas Pablo, Salido Luisa, Fernández-Vázquez Felipe, Hernández-García José Maria, Arzamendi Dabit. Percutaneous Mitral Valve Repair: Outcome Improvement with Operator Experience and a Second-Generation Device.. Journal of clinical medicine. 2021. DOI: 10.3390/jcm10040734.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.